Cabaletta Bio Equity 2024

Cabaletta Bio Aktienanalyse

What does Cabaletta Bio do?

Cabaletta Bio Inc is a biotech company founded in 2017, based in Philadelphia, Pennsylvania. The founders of the company are Michael Milone and Aimee Payne, both renowned experts in immunology. The business model of Cabaletta Bio Inc is to treat rare diseases using T-cell therapies. T-cell therapy is a form of immunotherapy where the patient's own T-cells, which have been taken from their blood, are genetically modified and then reintroduced to the patient. This process is intended to enable the patient's T-cells to recognize and fight specific diseased cells. Cabaletta Bio Inc focuses on developing therapies for rare autoimmune diseases and difficult-to-treat cancers. The company specializes in the development of CAR-T cell therapies (CAR-T stands for Chimeric Antigen Receptor) that enable the patient's T-cells to attack specific tumor or autoimmune cells in the body. Novel CAR-T cell technologies have been developed to allow the T-cells to recognize disease-specific antigens on cell surfaces. This way, the T-cells can selectively target and destroy diseased cells. Cabaletta Bio Inc is working on various areas of T-cell therapy development. The first area involves developing therapies for rare autoimmune diseases such as systemic scleroderma, Juvenile syndrome, or pemphigus vulgaris. The company has initiated clinical trials and collaborates with other research institutions and companies to advance the development of CAR-T cell therapies. Another area of focus for Cabaletta Bio Inc is treating cancers that are difficult to treat and lack therapeutic options, such as leukemia, solid tumors, or sarcomas. Identifying and targeting specific cells for these types of cancers is particularly challenging. Therefore, the company is actively working to develop novel CAR-T cell technologies that enable the T-cells to recognize and combat diseased cells. Currently, Cabaletta Bio Inc does not offer any commercial products as it is still in the phase of clinical research and development. However, the company aims to advance the development of T-cell therapies and make its technology accessible to patients with rare and difficult-to-treat diseases. Overall, Cabaletta Bio Inc has received recognition and support from leading scientists and organizations in recent years. The company has received several awards and accolades for its work, including the New Frontier Award from the National Organization for Rare Disorders (NORD) and the Fast Track Award from the US Food and Drug Administration (FDA). Cabaletta Bio Inc collaborates closely with various research institutions, universities, and companies to improve its technology and develop new therapies. In summary, Cabaletta Bio Inc is an emerging biotech company specializing in the development of T-cell therapies. The company aims to treat rare and difficult-to-treat diseases and make its technology accessible to patients. Although the company currently does not offer commercial products, it has received recognition and support from leading scientists and organizations in recent years and collaborates closely with various research institutions, universities, and companies to improve its technology and develop new therapies. Cabaletta Bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Cabaletta Bio's Equity

Cabaletta Bio's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cabaletta Bio's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cabaletta Bio's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cabaletta Bio's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cabaletta Bio’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cabaletta Bio stock

What is the equity of Cabaletta Bio this year?

Cabaletta Bio has equity of 236.2 M USD this year.

What was the equity of Cabaletta Bio compared to the previous year?

The equity of Cabaletta Bio has increased/decreased by 126.03% increased compared to the previous year.

What impact does a high equity have on investors of Cabaletta Bio?

A high equity is advantageous for investors of Cabaletta Bio as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Cabaletta Bio?

A low equity can be a risk for investors of Cabaletta Bio, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Cabaletta Bio affect the company?

An increase in equity of Cabaletta Bio can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Cabaletta Bio affect the company?

A reduction in equity of Cabaletta Bio can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Cabaletta Bio?

Some factors that can affect the equity of Cabaletta Bio include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Cabaletta Bio so important for investors?

The equity of Cabaletta Bio is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Cabaletta Bio take to change the equity?

To change equity, Cabaletta Bio can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Cabaletta Bio pay?

Over the past 12 months, Cabaletta Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cabaletta Bio is expected to pay a dividend of 0 USD.

What is the dividend yield of Cabaletta Bio?

The current dividend yield of Cabaletta Bio is .

When does Cabaletta Bio pay dividends?

Cabaletta Bio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cabaletta Bio?

Cabaletta Bio paid dividends every year for the past 0 years.

What is the dividend of Cabaletta Bio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cabaletta Bio located?

Cabaletta Bio is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cabaletta Bio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cabaletta Bio from 9/14/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/14/2024.

When did Cabaletta Bio pay the last dividend?

The last dividend was paid out on 9/14/2024.

What was the dividend of Cabaletta Bio in the year 2023?

In the year 2023, Cabaletta Bio distributed 0 USD as dividends.

In which currency does Cabaletta Bio pay out the dividend?

The dividends of Cabaletta Bio are distributed in USD.